How Cannabinoids Regulate Nausea, Vomiting, and Gut Pain
A review of cannabinoid receptors throughout the GI tract found strong evidence for their role in regulating nausea and vomiting, but limited and unsupportive clinical data for visceral pain conditions like IBS.
Quick Facts
What This Study Found
This review mapped cannabinoid receptors (CB1, CB2, and potentially GPR55) throughout the gastrointestinal tract and examined their roles in food intake, nausea, gastric secretion, motility, visceral sensation, inflammation, and cell proliferation.
The strongest evidence supported cannabinoid involvement in regulating nausea and vomiting, where the endocannabinoid system has provided new mechanistic insights. For visceral pain, animal models consistently showed that cannabinoids reduced sensitivity, but clinical data in IBS patients was scarce and did not support benefit.
Emerging drug targets, particularly FAAH and MAGL inhibitors, showed promise in animal studies but lacked human validation. The review highlighted that compounds acting on these targets could avoid the psychoactive side effects of direct cannabinoid receptor agonists.
Key Numbers
Three cannabinoid receptor types identified in the GI tract (CB1, CB2, GPR55); FAAH and MAGL inhibitors identified as novel drug targets; IBS clinical data described as scarce and not supportive
How They Did This
Narrative review of basic science and clinical literature on cannabinoid receptors and endocannabinoid signaling in the gastrointestinal tract.
Why This Research Matters
The GI tract contains a dense network of cannabinoid receptors, making it a logical therapeutic target. But this review revealed a gap between promising preclinical findings and disappointing clinical results, particularly for pain conditions.
The Bigger Picture
The future of cannabinoid-based GI therapy may lie not in traditional THC-like drugs but in compounds that boost endocannabinoid levels (FAAH/MAGL inhibitors) or act only on peripheral receptors, avoiding central nervous system side effects.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Clinical data for GI applications was limited at the time. Animal model results may not translate to humans. Did not address cannabinoid hyperemesis syndrome in detail.
Questions This Raises
- ?Will peripherally-acting cannabinoid drugs prove effective for IBS and other functional GI disorders?
- ?Can FAAH/MAGL inhibitors deliver clinical benefits without psychoactive side effects?
- ?How does chronic cannabis use affect GI cannabinoid receptor function?
Trust & Context
- Key Stat:
- Animal models support visceral pain relief; clinical IBS data does not
- Evidence Grade:
- Comprehensive narrative review of basic science and clinical evidence, limited by sparse human data for GI pain applications.
- Study Age:
- Published in 2015. Research on cannabinoids for GI conditions has continued, though clinical breakthroughs remain elusive.
- Original Title:
- The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.
- Published In:
- Current gastroenterology reports, 17(2), 429 (2015)
- Authors:
- Malik, Zubair, Baik, Daniel, Schey, Ron
- Database ID:
- RTHC-01008
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis help with IBS?
As of this 2015 review, animal studies showed cannabinoids could reduce visceral pain sensitivity, but clinical data in IBS patients was scarce and did not support benefit. The disconnect between animal and human results remains an active area of research.
Why does cannabis affect the gut?
The gastrointestinal tract contains cannabinoid receptors (CB1, CB2, and GPR55) that regulate motility, secretion, inflammation, and pain sensation. Cannabis compounds activate these receptors, producing effects throughout the digestive system.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01008APA
Malik, Zubair; Baik, Daniel; Schey, Ron. (2015). The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.. Current gastroenterology reports, 17(2), 429. https://doi.org/10.1007/s11894-015-0429-1
MLA
Malik, Zubair, et al. "The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.." Current gastroenterology reports, 2015. https://doi.org/10.1007/s11894-015-0429-1
RethinkTHC
RethinkTHC Research Database. "The role of cannabinoids in regulation of nausea and vomitin..." RTHC-01008. Retrieved from https://rethinkthc.com/research/malik-2015-the-role-of-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.